ClinicalTrials.gg
RecruitingNCT07405658Updated Nov 20, 2026

Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Early Detection of Kawasaki Disease

An observational study in Kawasaki Disease, Chest X-ray for Clinical Evaluation and Mucocutaneous Lymph Node Syndrome, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 0 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 20, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
20,000
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China — 8 open to participants now, 8 under way, 2 of them phase 3. Mucocutaneous Lymph Node Syndrome · China.

Started
2026
with 2 others
Observational
8 of 16
4 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Among the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, this one is one of 3 that started in 2026, is one of 8 observational ones, and was the 14th registered.

Mucocutaneous Lymph Node Syndrome

62 studies on the registry are indexed under Mucocutaneous Lymph Node Syndrome; 17 are open to participants now.

Browse Mucocutaneous Lymph Node Syndrome studies →

Open to participants now

8 of the 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Mucocutaneous Lymph Node Syndrome studies recruiting now, 1 (8%) sets no upper age limit and 11 (92%) stop at 75 or younger; 12 take children under 18; 2 take healthy volunteers.

This study: 0 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Mucocutaneous Lymph Node Syndrome with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to develop an AI-based early warning system for Kawasaki Disease (KD) using chest X-rays (CXR) in children diagnosed with Kawasaki Disease. The main question[s] it aims to answer are:

  1. Can AI modeling of CXR features help identify high-risk KD patients earlier than current diagnostic methods?
  2. Can the AI system predict the optimal IVIG treatment window and coronary artery risks in KD patients?

Participants will:

Provide retrospective data on chest X-rays and clinical data (CRP, coronary ultrasound, etc.) Allow analysis of CXR features using deep learning models to extract relevant patterns Have their data incorporated into a federated learning model to ensure privacy and data security

Read the detailed description
  1. Research Background and Clinical Pain Points Kawasaki Disease (KD) is a leading cause of acquired heart disease in children. Traditional diagnosis relies on subjective symptoms such as fever lasting ≥5 days and rashes, leading to two major problems: delayed diagnosis, with 30% of atypical patients missing the optimal IVIG treatment window (fever duration of 5-10 days); and coronary artery damage: delaying treatment for ≥7 days increases the risk of coronary dilation by 47%. The current AHA standards have only a 35% sensitivity for children with fever ≤3 days, highlighting the urgent need to establish an objective early warning system.
  2. Research Objectives and Technical Approach Core breakthrough: First time using routine chest X-rays (CXR) to develop an AI-based early warning model.

    Technical path: Multi-center data integration, collection of CXR and clinical data (clinical symptoms, laboratory tests, coronary ultrasound, etc.), and a federated learning framework to ensure privacy and security. Exploration of imaging biomarkers and CXR features that are invisible to the human eye, as well as the development of a multi-modal dynamic early warning model.

    Dual-path CNN to extract CXR features → Graph neural networks to integrate laboratory indicators → Diagnosis model to output the risk score of kawasaki disease.↑

  3. Innovation Advantages and Clinical Value Early-warning performance was strong by day 3 of fever, achieving a pre-trial sensitivity of 87.2% for Kawasaki disease, while providing individualized IVIG treatment windows and predicted coronary-artery risk. The lightweight model (less than 50MB) is adaptable for use in primary care settings.

    Clinical pathway:

    AI identifies high-risk children → Priority for echocardiography → IVIG treatment window advanced → Reduction in cardiovascular complications.

    The ultimate goal is to shorten diagnosis time and reduce cardiovascular complications of KD patients in China.

  4. Validation Plan and Results Translation

    Three-phase validation:

    Internal: 5-fold cross-validation (AUC ≥0.88) External: Blind testing in 3 hospitals (sensitivity >85%, specificity >80%) Clinical: Real-time deployment in emergency settings (response time ≤15 seconds) Results translation: 1-2 peer-reviewed journal publications and 1-2 patent filings; facilitating early identification of Kawasaki disease, thereby improving clinical outcomes.

  5. Key Conclusion This study aims to decode objective biomarkers such as pulmonary artery vascular signs in CXR images and construct the AI-CXR early warning system for KD. It will break through the current reliance on fever duration and subjective symptoms, providing support for early diagnosis and improving patient outcomes.
03

Conditions studied

  • Kawasaki Disease
  • Chest X-ray for Clinical Evaluation
  • Mucocutaneous Lymph Node Syndrome

Keywords

  • Kawasaki Disease
  • Artificial Intelligence
  • Mucocutaneous lymph node syndrome
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The case group consists of children diagnosed with Kawasaki Disease (KD) over the past 10 years. The inclusion criteria include: Children diagnosed with Kawasaki Disease based on clinical symptoms and confirmed by medical records.

The control group consists of data from patients with fever lasting ≥3 days, matched to the KD cohort based on diagnosis year, month, and clinical characteristics.

The study focuses on examining the relationship between chest X-ray features and Kawasaki Disease in these patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Case group

    • The age of seeking medical treatment is less than or equal to 18 years old; ·The medical record system diagnosis contains the diagnosis of "Kawasaki Disease", "mucocutaneous lymph node syndrome" or "IVIG non-response Kawasaki disease"
    • At least one complete chest X-ray examination data (images and reports) is available during the same hospitalization
  2. Control group

    • The age of seeking medical treatment is less than or equal to 18 years old
    • The same period as the case group
    • Fever lasts for 3 days or more
    • Rule out the possibility of diagnosing Kawasaki disease

Exclusion criteria

Exclusion Criteria:

  1. Case group

    • Chest X-ray quality issues: Severe artifacts, overexposure/underexposure leading to inability to assess key structures
    • Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever Inability to determine the final diagnosis (such as loss to follow-up, diagnosis in doubt)
  2. Control group

    • Chest X-ray quality issues: Severe artifacts, overexposure/underexposure leading to inability to assess key structures
    • Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever
    • Inability to make a clear final diagnosis (such as loss to follow-up, questionable diagnosis)
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
20,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Case group

    Inclusion criteria: (1) The age of seeking medical treatment is less than or equal to 18 years old; (2) The medical record system diagnosis contains the diagnosis of "Kawasaki Disease", "mucocutaneous lymph node syndrome" or "IVIG non-response Kawasaki disease". (3) At least one complete chest X-ray examination data (images and reports) is available during the same hospitalization. Exclusion criteria: (1) Chest X-ray quality issues: Severe artifacts, overexposure/underexposure leading to inability to assess key structures. (2) Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever. (3) Inability to determine the final diagnosis (such as loss to follow-up, diagnosis in doubt).

    Diagnostic Test: AI-Based Early Warning System for Kawasaki Disease

  • Control group

    Inclusion criteria: (1) The age of seeking medical treatment is less than or equal to 18 years old; (2) The same period as the case group; (3) Fever lasts for 3 days or more; (4) Rule out the possibility of diagnosing Kawasaki disease Exclusion criteria: (1) Chest X-ray quality issues: Severe artifacts, overexposure/underexposure leading to inability to assess key structures. (2) Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever. (3) Inability to make a clear final diagnosis (such as loss to follow-up, questionable diagnosis)

    Diagnostic Test: AI-Based Early Warning System for Kawasaki Disease

Interventions

  • Diagnostic testAI-Based Early Warning System for Kawasaki Disease

    This study utilizes an AI-based early warning system for Kawasaki Disease (KD) to predict the optimal IVIG treatment window and assess coronary risk. The system analyzes chest X-ray (CXR) images and integrates them with clinical data such as CRP levels and clinical symptoms. The intervention involves the development of a multi-modal dynamic prediction model that uses a dual-pathway convolutional neural network (CNN) to extract relevant CXR features and a graph neural network to integrate laboratory indicators. The AI system outputs a prediction of the IVIG treatment window and estimates the risk of coronary artery damage. This early warning system aims to reduce diagnosis time and improve treatment outcomes by identifying high-risk KD patients earlier, enabling timely intervention and personalized treatment plans. The model is designed to be lightweight (under 50MB) to be easily applicable in primary care settings.

06

What researchers measure

Primary outcomes

  1. Area Under Curve

    Time frame: Up to 14 days after fever onset

  2. sensitivity

    Time frame: Up to 14 days after fever onset

  3. specificity

    Time frame: Up to 14 days after fever onset

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to confidentiality concerns, participant consent restrictions, and the need to comply with ethical and legal standards, Individual Participant Data (IPD) from this study will not be shared. The data contains sensitive health information that is protected by privacy regulations, and we do not have explicit consent from participants to share their data for secondary analysis. Additionally, institutional policies and data security requirements further restrict the release of IPD.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Feb 12, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine is now Recruiting
Nov 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, ChinaContact added w•••@xinhuamed.com.cn · •••1356Contact added 1•••@sjtu.edu.cn · •••5669
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, ChinaContact added w•••@xinhuamed.com.cn · •••1356Contact added 1•••@sjtu.edu.cn · •••5669
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07405658
Collaborators
Children's Hospital of Soochow University, Hunan Provincial People's Hospital, Women and Children Hospital of Qinghai Province, Yangzhou No.1 People's Hospital
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Feb 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Jian Wang, Doctoral Degree
Contact
wangjian@xinhuemed.com.cn
86-15900861356
Bo Wang, PhD Candidate
Contact
18bowang@sjtu.edu.cn
86-19921875669
Kun Sun, Doctoral degree
study chair · Xinhua hospital affiliated with Shanghai Jiao Tong university school of medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion